University Hospitals of Derby and Burton NHS Foundation Trust

**Paediatrics: Dobutamine** 

| Presentation:  | Solution for injection 5mg/ml, 50ml ampoules   |  |  |  |  |
|--|--|--|--|--|--|
| Indication:  | Inotropic support  |  |  |  |  |
| Dose:  | Neonate and Child: Initially 5 micrograms/kg/minute, then adjusted according to response to 2–20 micrograms/kg/minute, doses as low as 0.5–1 microgram/kg/minute have been used  |  |  |  |  |
| Route of administration:   | Continuous intravenous infusion via SMART pump preferably via <b>central venous access device</b> (if central venous access unavailable, give via large peripheral vein and do frequent VIP scoring)   |  |  |  |  |
| Instructions for preparation:  | Preparation of syringe for CENTRAL LINE use:<br>NB. Rate will vary with weight as using fixed concentrations. Do not use double or quadruple<br>strength syringes.   |  |  |  |  |
|  | <ul> <li>Patients &lt;6.5kg:</li> <li>Measure 125mg dobutamine (25ml)</li> <li>Dilute to a final volume of 50ml with glucose 5% or sodium chloride 0.9%</li> <li>A dose of 5 microgram/kg/minute will be provided by a rate of 6 × weight 50 ml/hour</li> </ul>  |  |  |  |  |
|  | <ul> <li>Patients ≥6.5kg:</li> <li>Measure 250mg dobutamine (50ml)</li> <li>Does not require dilution</li> <li>A dose of 5 micrograms/kg/minute will be provided by a flow rate of 3×weight 50 ml/hr</li> </ul>  |  |  |  |  |
|  | <ul> <li>Preparation of syringe for PERIPHERAL use in exceptional circumstances:</li> <li>Prepare a dobutamine 2mg/ml syringe: <ul> <li>Measure 100mg dobutamine (20ml)</li> <li>Dilute to a final volume of 50ml with sodium chloride 0.9% or 5% glucose</li> <li>A dose of 5 microgram/kg/minute will be provided by a rate of <sup>3 × weight</sup>/<sub>20</sub> ml/hour</li> <li>Extravasation can lead to necrosis and may necessitate amputation of the affected limb so the vein should be monitored regularly and VIP scored to facilitate early identification of extravasation</li> </ul> </li> </ul> |  |  |  |  |
|  | Dobutamine injection may turn pink due to a slight oxidation of the drug. Such solutions are safe to use as there is no significant loss of potency. Discard diluted dobutamine solution after 24 hours.   |  |  |  |  |
| Prescribing<br><u>QHB</u> -Prescribe o<br><u>RDH</u> - Prescribe o<br>To calculate con<br>mg/ml.<br><i>e.g.</i> <u>125mg</u> = 2.5 | n_Meditech<br>on paper chart<br>centration of infusion for SMART pumps, divide the amount of drug in the syringe by 50 to get<br>img/ml  |  |  |  |  |
|  |  |  |  |  |  |

University Hospitals of Derby and Burton NHS Foundation Trust

| Example prescription for 5 kg infant: |   |   |   |                   |                       |                         |                  |  |
|---------------------------------------|---|---|---|-------------------|-----------------------|-------------------------|------------------|--|
| Drug Drug amour                       |   | it in syringe   | Diluent   |                   | Total volume (ml)     | Route                   |                  |  |
| Dobutami ne                           |   | 125mg   |   | <i>Glucose 5%</i> |                       | 50ml                    | LL               |  |
| Start date                            | Drug concentra  | ation per ml  | Infusion range  | N                 | lin                   | Max                     | Name, Sig, Bleep |  |
| 6/3/18                                | 2 5ma   | 2 Ema Iml   |   | 2microgra         | ms/kg/min             | 20micrograms/kg/min     | A.Doctor         |  |
| Pharm                                 | 2.51119   | /   | ml/hr   | 0.24ml/hr         |                       | 2.4ml/hr                | #1234            |  |
| Directions                            | s for   | •   | Load Syrin  | ge, prime li      | ne using the          | e pump for accurate dos | sing.            |  |
| administr                             | ation via   | •   | • Open 'Children' folder then open 'doBUTamine' programme.                          |                   |                       |                         |                  |  |
| SMART pu                              | ump   | •   | <ul> <li>Using DATA chevrons enter concentration in mg/ml and confirm</li> </ul>    |                   |                       |                         |                  |  |
|                                       |   | •   | Enter Childs weight in kg and confirm   |                   |                       |                         |                  |  |
|                                       |   | •   | Enter the dose in micrograms/kg/min   |                   |                       |                         |                  |  |
|                                       |   | •   | • Visually confirm the rate (ml/h) against the prescribed dose (micrograms/kg/min)  |                   |                       |                         |                  |  |
|                                       |   | •   | Perform STOP moment with medical team (Pump against prescription)                   |                   |                       |                         |                  |  |
|                                       |   | •   | Connect to Child  |                   |                       |                         |                  |  |
|                                       |   |   | Press start button  |                   |                       |                         |                  |  |
| Known co                              | mpatibility   | Compa   | Compatible: Adrenaline, Atracurium, Caffeine, Ceftazidime, Ciprofloxacin, Dopamine, |                   |                       |                         |                  |  |
| issues                                |   | Flucon  | Fluconazole, Furosemide (if in NS), Insulin, Midazolam, Morphine, Noradrenaline,    |                   |                       |                         |                  |  |
|                                       |   | Pancu   | Pancuronium, Potassium chloride, Ranitidine   |                   |                       |                         |                  |  |
|                                       |   | Incompatible: Aciclovir, Calcium salts, Heparin, Magnesium sulphate,              |   |                   |                       |                         |                  |  |
|                                       |   | Piperacillin/tazobactam, Sodium bicarbonate                                       |   |                   |                       |                         |                  |  |
| Additiona                             | l Comments:   | Tolerance may develop with continuous infusions longer than 72 hours requiring an |   |                   |                       |                         |                  |  |
|                                       | increase in dose. Avoid abrupt withdrawal. Reduce dose gradually to avoid unnecessa |   |   | ecessary          |                       |                         |                  |  |
|                                       |   | hypotension.  |   |                   |                       |                         |                  |  |
| Ampoules of dobutamine                |   |   | utamine con   | ntain sodiur      | n metabisulphite whic | h can cause a           | lergic type      |  |
|                                       |   | reactions, including anaphylactic symptoms  |   |                   |                       |                         |                  |  |

Note: The contents of this monograph should be read in conjunction with information available in the BNFC and Medusa

## **References:**

CoMET dosing chart v 2021 02 10

British National Formulary for Children, accessed via <u>www.medicinescomplete.com</u> Accessed December 2023 SPC for accessed via <u>www.medicines.org.uk</u> Accessed December 2023

Medusa Injectable Medicines Guide, accessed via http://medusa.wales.nhs.uk Accessed December 2023 Trissel LA (Ed), Handbook on Injectable Drugs, accessed via www.medicinescomplete.com Accessed December 2023



## **Document control sheet**

| GUIDELINE NUMBER                     | MONO-PAEDS/806/23                     |
|--------------------------------------|---------------------------------------|
| AREA IN WHICH THIS MONOGRAPH APPLIES | Paediatrics, Children's hospital, RDH |
|                                      |                                       |

| DIVISIONAL AUTHORISATION          |            |  |  |
|-----------------------------------|------------|--|--|
| GROUP                             | DATE       |  |  |
| Paediatric monograph review group | 12/12/2023 |  |  |

| AUTHORS                        |  |             |  |
|--------------------------------|--|-------------|--|
| Author                         | Position                                 | Date        |  |
| Written by:<br>Lisa Taylor     | Advanced Pharmacist Women's & Children's | August 2017 |  |
| Checked by:<br>Kevin Inglesant | Advanced Pharmacist Women's & Children's | August 2017 |  |

## If review:

|                 | Position                        | Date          |
|-----------------|---------------------------------|---------------|
| Reviewed by:    | Advanced Pharmacist Women's &   | October 2018  |
| Kevin Inglesant | Children's                      |               |
|                 |                                 |               |
| Checked by:     | Advanced Pharmacist Women's and | December 2023 |
| Lamia Ahmed     | Children's                      |               |

Change history:

| Changes<br>Reference | Change details  | Date          |
|----------------------|---|---------------|
| 1                    | Updated concentration of dobutamine ampoules from 12.5mg/mL to 5mg/mL | 25/7/18       |
| 2                    | Changed to fixed concentration infusion based on CoMET guideline      | 22/10/18      |
| 3                    | Prescribing instructions for QHB and RDH                              | December 2023 |